Dissecting signaling pathways in hepatocellular carcinoma: New perspectives in medical therapy

Future Oncology

Volumn 10, Issue 2, 2014, Pages 285-304

  Fornaro, Lorenzo ^a   Vivaldi, Caterina ^b   Caparello, Chiara ^b   Sacco, Rodolfo ^b   Rotella, Virginia ^a   Musettini, Gianna ^b   Luchi, Sauro ^c   Baldini, Edi Editta ^a   Falcone, Alfredo ^b   Masi, Gianluca ^b  

^a CAMPO DI MARTE HOSPITAL   (Italy)

^b UNIVERSITY HOSPITAL OF PISA   (Italy)

^c Division of Infectious Disease   (Italy)

Author keywords

AKT; EGFR; ERK; hepatocellular carcinoma; HGF; MEK; MET; mTOR; PI3K; sorafenib

Indexed keywords

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, HEPATOCELLULAR; HUMANS; LIVER NEOPLASMS; MOLECULAR TARGETED THERAPY; SIGNAL TRANSDUCTION;

EID: 84893861917     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.13.181     Document Type: Review

References (100)

1. Maluccio M, Covey A. Recent progress in understanding, diagnosing, and treating hepatocellular carcinoma. CA Cancer J. Clin. 62, 394-399 (2012).
2. Llovet JM, Ricci S, Mazzaferro V et al.; SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N Engl. J. Med. 359, 378-390 (2008).
3. Cheng AL, Kang YK, Chen Z et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a Phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 10, 25-34 (2009).
4. Cao H, Phan H, Yang LX. Improved chemotherapy for hepatocellular carcinoma. Anticancer Res. 32, 1379-1386 (2012).
5. Psyrri A, Arkadopoulos N, Vassilakopoulou M et al. Pathways and targets in hepatocellular carcinoma. Expert Rev. Anticancer Ther. 12, 1347-1357 (2012).
6. Miki D, Ochi H, Hayes CN, Aikata H, Chayama K. Hepatocellular carcinoma: towards personalized medicine. Cancer Sci. 103, 846-850 (2012).
7. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 132, 2557-2576 (2007). (Pubitemid 46890874)
8. Levrero M. Viral hepatitis and liver cancer: the case of hepatitis C. Oncogene 25, 3834-3847 (2006). (Pubitemid 43980479)
9. Elsharkawy AM, Mann DA. Nuclear factor-kappaB and the hepatic inflammation-fibrosis-cancer axis. Hepatology 46, 590-597 (2007). (Pubitemid 47344795)
10. Nakagawa H, Maeda S, Yoshida H et al. Serum IL-6 levels and the risk for hepatocarcinogenesis in chronic hepatitis C patients: an analysis based on gender differences. Int. J. Cancer 125, 2264-2269 (2009).
11. Whittaker S, Marais R, Zhu AX. The role of signaling pathways in the development and treatment of hepatocellular carcinoma. Oncogene 29, 4989-5005 (2010).
12. Chung YH, Kim JA, Song BC et al. Expression of transforming growth factor-alpha mRNA in livers of patients with chronic viral hepatitis and hepatocellular carcinoma. Cancer 89, 977-982 (2000).
13. Huh CG, Factor VM, Sanchez A et al. Hepatocyte growth factor/c-met signaling pathway is required for efficient liver regeneration and repair. Proc. Natl Acad. Sci. USA 101, 4477-4482 (2004). (Pubitemid 38437436)
14. Comoglio PM, Trusolino L. Invasive growth: from development to metastasis. J. Clin. Invest. 109, 857-862 (2002). (Pubitemid 34275105)
15. Boix L, Rosa JL, Ventura F et al. c-Met mRNA overexpression in human hepatocellular carcinoma. Hepatology 19, 88-91 (1994). (Pubitemid 24020476)
16. Suzuki K, Hayashi N, Yamada Y et al. Expression of the c-met protooncogene in human hepatocellular carcinoma. Hepatology 20, 1231-1236 (1994). (Pubitemid 24323571)
17. Wu F, Wu L, Zheng S et al. The clinical value of hepatocyte growth factor and its receptor c-Met for liver cancer patients with hepatectomy. Dig. Liver Dis. 38, 490-497 (2006). (Pubitemid 44356232)
18. Kaposi-Novak P, Lee JS, Gomez-Quiroz L, Coulouarn C, Factor VM, Thorgeirsson SS. Met-regulated expression signature defines a subset of human hepatocellular carcinomas with poor prognosis and aggressive phenotype. J. Clin. Invest. 116, 1582-1595 (2006).
19. Wang ZL, Liang P, Dong BW, Yu XL, Yu de J. Prognostic factors and recurrence of small hepatocellular carcinoma after hepatic resection or microwave ablation: a retrospective study. J. Gastrointest. Surg. 12, 327-337 (2008).
20. Treiber G. mTOR inhibitors for hepatocellular cancer: a forward-moving target. Expert Rev. Anticancer Ther. 9, 247-261 (2009).
21. Villanueva A, Chiang DY, Newell P et al. Pivotal role of mTOR signaling in hepatocellular carcinoma. Gastroenterology 135, 1972-1983 (2008).
22. Huynh H, Nguyen TT, Chow KH, Tan PH, Soo KC, Tran E. Over-expression of the mitogen-activated protein kinase (MAPK) kinase (MEK)-MAPK in hepatocellular carcinoma: its role in tumor progression and apoptosis. BMC Gastroenterology 3, 19 (2003).
23. Ballif BA, Blenis J. Molecular mechanisms mediating mammalian mitogen-activated protein kinase (MAPK) kinase (MEK)-MAPK cell survival signals. Cell Growth Differ. 12, 397-408 (2001). (Pubitemid 32762689)
24. Esteller M. Epigenetics in cancer. N. Engl. J. Med. 358, 1148-1159 (2008).
25. Esteller M. Epigenetics provides a new generation of oncogenes and tumour-suppressor genes. Br. J. Cancer 94, 179-183 (2006). (Pubitemid 43151531)
26. Yang B, Guo M, Herman JG, Clark DP. Aberrant promoter methylation profiles of tumor suppressor genes in hepatocellular carcinoma. Am. J. Pathol. 163, 1101-1107 (2003). (Pubitemid 37040145)
27. Zhong S, Yeo W, Tang MW, Wong N, Lai PB, Johnson PJ. Intensive hypermethylation of the CpG island of Ras association domain family 1A in hepatitis B virus-associated hepatocellular carcinomas. Clin. Cancer Res. 9, 3376-3382 (2003). (Pubitemid 37086674)
28. Ribatti D, Vacca A, Nico B, Sansonno D, Dammacco F. Angiogenesis and anti-angiogenesis in hepatocellular carcinoma. Cancer Treat. Rev. 32, 437-444 (2006). (Pubitemid 44309250)
29. Yamaguchi R, Yano H, Nakashima Y et al. Expression and localization of vascular endothelial growth factor receptors in human hepatocellular carcinoma and non-HCC tissues. Oncol. Rep. 7, 725-729 (2000).
30. Chao Y, Li CP, Chau GY et al. Prognostic significance of vascular endothelial growth factor, basic fibroblast growth factor, and angiogenin in patients with resectable hepatocellular carcinoma after surgery. Ann. Surg. Oncol. 10, 355-362 (2003). (Pubitemid 40486931)
31. Messerini L, Novelli L, Comin CE. Microvessel density and clinicopathological characteristics in hepatitis C virus and hepatitis B virus related hepatocellular carcinoma. J. Clin. Pathol. 57, 867-871 (2004). (Pubitemid 39061438)
32. Jeng KS, Sheen IS, Wang YC et al. Prognostic significance of preoperative circulating vascular endothelial growth factor messenger RNA expression in resectable hepatocellular carcinoma: a prospective study. World J. Gastroenterol. 10, 643-648 (2004).
33. Poon RT, Ho JW, Tong CS et al. Prognostic significance of serum vascular endothelial growth factor and endostatin in patients with hepatocellular carcinoma. Br. J. Surg. 91, 1354-1360 (2004). (Pubitemid 39331462)
34. Finn OJ. Cancer immunology. N. Engl. J. Med. 358, 2704-2715 (2008).
35. Oquiñena S, Iñarrairaegui M, Vila JJ, Alegre F, Zozaya JM, Sangro B. Spontaneous regression of hepatocellular carcinoma: three case reports and a categorized review of the literature. Dig. Dis. Sci. 54, 1147-1153 (2009).
36. Melero I, Hervas-Stubbs S, Glennie M, Pardoll DM, Chen L. Immunostimulatory monoclonal antibodies for cancer therapy. Nat. Rev. Cancer 7, 95-106 (2007). (Pubitemid 46160986)
37. Siegel AB, Cohen EI, Ocean A et al. Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma. J. Clin. Oncol. 26, 2992-2998 (2008).
38. Fang P, Hu JH, Cheng ZG et al. Efficacy and safety of bevacizumab for the treatment of advanced hepatocellular carcinoma: a systematic review of Phase II trials. PLoS One 7, e49717 (2012).
39. Zhu AX, Finn RS, Mulcahy MF et al. A Phase II study of ramucirumab as first-line monotherapy in patients (pts) with advanced hepatocellular carcinoma (HCC). J. Clin. Oncol. 28(s15), Abstract 4083 (2010).
40. Faivre S, Raymond E, Boucher E et al. Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, Phase II study. Lancet Oncol. 10, 794-800 (2009).
41. Zhu AX, Sahani DV, Duda DG et al. Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a Phase II study. J. Clin. Oncol. 27, 3027-3035 (2009).
42. Koeberle D, Montemurro M, Samaras P et al. Continuous sunitinib treatment in patients with advanced hepatocellular carcinoma: a Swiss Group for Clinical Cancer Research (SAKK) and Swiss Association for the Study of the Liver (SASL) multicenter II trial (SAKK 77/06). Oncologist 15, 285-292 (2010).
43. Cheng AL, Kang YK, Lin DY et al. Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized Phase III trial. J. Clin. Oncol. 31, 4067-4076 (2013).
44. Grothey A, Van Cutsem E, Sobrero A et al.; CORRECT Study Group. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, Phase 3 trial. Lancet 381, 303-312 (2013).
45. Demetri GD, Reichardt P, Kang YK et al. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, Phase 3 trial. Lancet 381, 295-302 (2013).
46. Wilhelm SM, Dumas J, Adnane L et al. Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. Int. J. Cancer 129, 245-255 (2011).
47. Finn RS, Blumenschein GR, Tolcher AW, Leong S, Boix O, Diefenbach K. Continuous-dose regorafenib (REG) in hepatocellular carcinoma (HCC): Phase I safety and pharmacokinetic (PK) study. J. Clin. Oncol. 30(s34), Abstract 300 (2012).
48. Bruix J, Tak WY, Gasbarrini A et al. Regorafenib as second-line therapy for intermediate or advanced hepatocellular carcinoma: multicentre, open-label, Phase II safety study. Eur. J. Cancer 49(16), 3412-3419 (2013).
49. Toh H, Chen P, Carr BI et al. Linifanib Phase II trial in 44 patients with advanced hepatocellular carcinoma (HCC). J. Clin. Oncol. 28(s15), Abstract 4038 (2010).
50. Cainap C, Qin S, Huang W et al. Phase III trial of linifanib versus sorafenib in patients with advanced hepatocellular carcinoma (HCC). J. Clin. Oncol. 31(Suppl. 34), Abstract 249 (2013).
51. Hsu PI, Chow NH, Lai KH et al. Implications of serum basic fibroblast growth factor levels in chronic liver diseases and hepatocellular carcinoma. Anticancer Res. 17(4A), 2803-2809 (1997).
52. Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat. Rev. Cancer 8(8), 592-603 (2008).
53. Park JW, Finn RS, Kim JS et al. Phase II, open-label study of brivanib as first-line therapy in patients with advanced hepatocellular carcinoma. Clin. Cancer Res. 17, 1973-1983 (2011).
54. Johnson PJ, Qin S, Park JW et al. Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized Phase III BRISK-FL study. J. Clin. Oncol. 31, 3517-3524 (2013).
55. Finn RS, Kang YK, Mulcahy M et al. Phase II, open-label study of brivanib as second-line therapy in patients with advanced hepatocellular carcinoma. Clin. Cancer Res. 18, 2090-2098 (2012).
56. Llovet JM, Decaens T, Raoul JL et al. Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized Phase III BRISK-PS study. J. Clin. Oncol. 31, 3509-3516 (2013).
57. Wedge SR, Kendrew J, Hennequin LF et al. AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. Cancer Res. 65, 4389-4400 (2005). (Pubitemid 40775678)
58. Alberts SR, Fitch TR, Kim GP et al. Cediranib (AZD2171) in patients with advanced hepatocellular carcinoma: a Phase II North Central Cancer Treatment Group clinical trial. Am. J. Clin. Oncol. 35, 329-333 (2012).
59. Zhu AX, Ancukiewicz M, Supko JG et al. Clinical, pharmacodynamic (PD), and pharmacokinetic (PK) evaluation of cediranib in advanced hepatocellular carcinoma (HCC): a Phase II study (CTEP 7147). J. Clin. Oncol. 30(s15), Abstract 4112 (2012).
60. Okita K, Kumada H, Ikeda K et al. Phase I/II study of E7080 (lenvatinib), a multitargeted tyrosine kinase inhibitor, in patients (pts) with advanced hepatocellular carcinoma (HCC): initial assessment of response rate. J. Clin. Oncol. 30(s4), Abstract 320 (2012).
61. Kanai F, Yoshida H, Tateishi R et al. A Phase I/II trial of the oral antiangiogenic agent TSU-68 in patients with advanced hepatocellular carcinoma. Cancer Chemother. Pharmacol. 67, 315-324 (2011).
62. O'Dwyer PJ, Giantonio BJ, Levy DE, Kauh JS, Fitzgerald DB, Benson AB. Gefitinib in advanced unresectable hepatocellular carcinoma: results from the Eastern Cooperative Oncology Group's study E1203. J. Clin. Oncol. 24(s18), Abstract 4143 (2006).
63. Philip PA, Mahoney MR, Allmer C et al. Phase II study of erlotinib (OSI-774) in patients with advanced hepatocellular cancer. J. Clin. Oncol. 23, 6657-6663 (2005). (Pubitemid 46190260)
64. Thomas MB, Chadha R, Glover K et al. Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma. Cancer 110, 1059-1067 (2007). (Pubitemid 47312872)
65. Ramanathan RK, Belani CP, Singh DA et al. A Phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer. Cancer Chemother. Pharmacol. 64, 777-783 (2009).
66. Bekaii-Saab T, Markowitz J, Prescott N et al. A multi-institutional Phase II study of the efficacy and tolerability of lapatinib in patients with advanced hepatocellular carcinomas. Clin. Cancer Res. 15, 5895-5901 (2009).
67. Zhu AX, Stuart K, Blaszkowsky LS et al. Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma. Cancer 110, 581-589 (2007). (Pubitemid 47106147)
68. Gruenwald Y, Wilkens L, Gebel M et al. A Phase II open-label study of cetuximab in unresectable hepatocellular carcinoma: final results. J. Clin. Oncol. 25(s18), Abstract 4598 (2007).
69. Goyal L, Muzumdar MD, Zhu AX. Targeting the HGF/c-MET pathway in hepatocellular carcinoma. Clin. Cancer Res. 19, 2310-2318 (2013).
70. Yau T, Sukeepaisarnjaroen W, Chao Y et al. A Phase I/II study of foretinib, an oral multikinase inhibitor targeting MET, RON, AXL, TIE-2, and VEGFR in advanced hepatocellular carcinoma (HCC). J. Clin. Oncol. 30(s15), Abstract 4108 (2012).
71. Verslype C, Cohn AL, Kelley RK et al. Activity of cabozantinib (XL184) in hepatocellular carcinoma: results from a Phase II randomized discontinuation trial (RDT). J. Clin. Oncol. 30(s15), Abstract 4007 (2012).
72. Santoro A, Simonelli M, Rodriguez-Lope C et al. A Phase-1b study of tivantinib (ARQ 197) in adult patients with hepatocellular carcinoma and cirrhosis. Br. J. Cancer 108, 21-24 (2013).
73. Santoro A, Rimassa L, Borbath I et al. Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled Phase 2 study. Lancet Oncol. 14, 55-63 (2013).
74. Chen L, Shiah HS, Chen CY et al. Randomized, Phase I, and pharmacokinetic (PK) study of RAD001, an mTOR inhibitor, in patients (pts) with advanced hepatocellular carcinoma (HCC). J. Clin. Oncol. 27(s15), Abstract 4587 (2009).
75. Zhu AX, Abrams TA, Miksad R et al. Phase 1/2 study of everolimus in advanced hepatocellular carcinoma. Cancer 117, 5094-5102 (2011).
76. Huynh H, Soo KC, Chow PK, Tran E. Targeted inhibition of the extracellular signal-regulated kinase kinase pathway with AZD6244 (ARRY-142886) in the treatment of hepatocellular carcinoma. Mol. Cancer Ther. 6, 138-146 (2007). (Pubitemid 46206676)
77. Huynh H. AZD6244 (ARRY-142886) enhances the antitumor activity of rapamycin in mouse models of human hepatocellular carcinoma. Cancer 116, 1315-1325 (2010).
78. Huynh H, Ngo VC, Koong HN et al. AZD6244 enhances the anti-tumor activity of sorafenib in ectopic and orthotopic models of human hepatocellular carcinoma (HCC). J. Hepatol. 52, 79-87 (2010).
79. Huynh H, Chow PK, Soo KC. AZD6244 and doxorubicin induce growth suppression and apoptosis in mouse models of hepatocellular carcinoma. Mol. Cancer Ther. 6, 2468-2476 (2007). (Pubitemid 47480412)
80. O'Neil BH, Goff LW, Kauh JS et al. Phase II study of the mitogen-activated protein kinase 1/2 inhibitor selumetinib in patients with advanced hepatocellular carcinoma. J. Clin. Oncol. 29, 2350-2356 (2011).
81. Lim HY, Yen CJ, Tak WY et al. A Phase II trial of MEK inhibitor BAY 86-9766 in combination with sorafenib as first-line systemic treatment for patients with unresectable hepatocellular carcinoma (HCC). J. Clin. Oncol. 30(s15), Abstract 4103 (2012).
82. Yeo W, Chung HC, Chan SL et al. Epigenetic therapy using belinostat for patients with unresectable hepatocellular carcinoma: a multicenter Phase I/II study with biomarker and pharmacokinetic analysis of tumors from patients in the Mayo Phase II Consortium and the Cancer Therapeutics Research Group. J. Clin. Oncol. 30, 3361-3367 (2012).
83. Palmer DH, Midgley RS, Mirza M et al. A Phase II study of adoptive immunotherapy using dendritic cells pulsed with tumor lysate in patients with hepatocellular carcinoma. Hepatology 49, 124-132 (2009).
84. Takayama T, Sekine T, Makuuchi M et al. Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial. Lancet 356, 802-807 (2000).
85. Heo J, Reid T, Ruo L et al. Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer. Nat. Med. 19, 329-336 (2013).
86. Sangro B, Gomez-Martin C, de la Mata M et al. A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C. J. Hepatol. 59, 81-88 (2013).
87. Chan SL, Mok T, Ma BB. Management of hepatocellular carcinoma: beyond sorafenib. Curr. Oncol. Rep. 14, 257-266 (2012).
88. Abou-Alfa GK, Johnson P, Knox JJ et al. Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial. JAMA 304, 2154-2160 (2010).
89. Hsu CH, Yang TS, Hsu C et al. Efficacy and tolerability of bevacizumab plus capecitabine as first-line therapy in patients with advanced hepatocellular carcinoma. Br. J. Cancer 102, 981-986 (2010).
90. Sun W, Sohal D, Haller DG et al. Phase 2 trial of bevacizumab, capecitabine, and oxaliplatin in treatment of advanced hepatocellular carcinoma. Cancer 117, 3187-3192 (2011).
91. Zhu AX, Blaszkowsky LS, Ryan DP et al. Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma. J. Clin. Oncol. 24, 1898-1903 (2006). (Pubitemid 46638989)
92. Chiorean EG, Ramasubbaiah R, Yu M et al. Phase II trial of erlotinib and docetaxel in advanced and refractory hepatocellular and biliary cancers: Hoosier Oncology Group GI06-101. Oncologist 17, 13 (2012).
93. Patt AD, Baron VA, Parks A et al. Phase II trial of gemcitabine (G), oxaliplatin (O), and erlotinib (T) for the treatment of hepatocellular carcinoma (HCC) and biliary tree cancers (BTC). J. Clin. Oncol. 28(s15), Abstract 4153 (2010).
94. Asnacios A, Fartoux L, Romano O et al. Gemcitabine plus oxaliplatin (GEMOX) combined with cetuximab in patients with progressive advanced stage hepatocellular carcinoma: results of a multicenter Phase 2 study. Cancer 112, 2733-2739 (2008). (Pubitemid 351969218)
95. Sanoff HK, Bernard S, Goldberg RM et al. Phase II study of capecitabine, oxaliplatin, and cetuximab for advanced hepatocellular carcinoma. Gastrointest. Cancer Res. 4, 78-83 (2011).
96. Fornaro L, Masi G, Loupakis F, Vasile E, Falcone A. Palliative treatment of unresectable metastatic colorectal cancer. Expert Opin. Pharmacother. 11, 63-77 (2010).
97. Thomas MB, Morris JS, Chadha R et al. Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma. J. Clin. Oncol. 27, 843-850 (2009).
98. Philip PA, Mahoney MR, Holen KD et al. Phase 2 study of bevacizumab plus erlotinib in patients with advanced hepatocellular cancer. Cancer 118, 2424-2430 (2012).
99. Zhu AX, Rosmorduc O, Evans J et al. SEARCH: a Phase III, randomized, doubleblind, placebo-controlled trial of sorafenib plus erlotinib in patients with hepatocellular carcinoma (HCC). Ann. Oncol. 23(Suppl. 9), Abstract LBA2 (2012).
100. Finn RS, Poon RTP, Yau T et al. Phase I study of everolimus in combination with sorafenib in patients with advanced hepatocellular carcinoma (HCC). J. Clin. Oncol. 29(Suppl. 15), Abstract 4074 (2011).